Related Experiment Video
Updated: May 11, 2026

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
Delayed Serotonin Syndrome Following the Concurrent Use of an Unregulated Supplement and Selective Serotonin Reuptake
Win Win Kyi1, Elba B Peter2, Keiko Carter3
1General Medicine, Royal Gwent Hospital, Newport, GBR.
Abstract:
Serotonin syndrome results from an excess accumulation of serotonin, which can be life-threatening if not promptly recognized. It typically arises from recent changes in antidepressant regimens or interactions with other medications and supplements. The diagnosis is clinical and features a spectrum of symptoms, from mild agitation and tremor to severe complications such as renal failure, seizures, and death. Early identification and intervention are crucial, typically resulting in the resolution of symptoms within 24 hours. With antidepressant use on the rise, serotonin syndrome is increasingly encountered in clinical practice. Patients prescribed serotonergic agents should be made aware of toxicity signs and cautioned about potential interactions with over-the-counter supplements. This report describes a 27-year-old lady who presented with delayed onset of serotonin toxicity symptoms after two months of taking CutXtreme, an unregulated weight-loss supplement popularized on social media. She had a stable history on sertraline with no previous adverse effects. Discontinuation of both sertraline and CutXtreme, combined with supportive care, led to complete symptom resolution within 24 hours. This case emphasizes the importance of patient education on the potential risks of unregulated supplements, along with early recognition of serotonin toxicity and the need for clinical vigilance in unusual or atypical serotonin syndrome presentations.
More Related Videos
08:49Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Related Concept Videos
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...